Cardiovascular Risk in Psoriasis: A Population-Based Analysis with Assessment of the Framingham Risk Score
Table 1
Characteristics and cardiovascular risk factors of patients with psoriasis and no prior cardiovascular disease. Comparison of patients with enough information to compute the Framingham risk score (FRS) to those without enough information for the FRS.
Characteristic
Patients without FRS
Patients with FRS
P value
Prevalent psoriasis
224
149 (67%)
1197
792 (66%)
0.92
Age, years
224
45.0 ± 12
1197
51.3 ± 13
<0.001
Male sex
224
150 (67%)
1197
565 (47%)
<0.001
Systolic blood pressure, mmHg
76
130.0 ± 13.1
1155
130.6 ± 12.7
0.78
Diastolic blood pressure, mmHg
40
78.1 ± 11.3
781
77.5 ± 11.1
0.50
Use of antihypertensive medications
224
1 (0%)
1197
225 (19%)
<0.001
Current smoking
224
38 (17%)
1197
190 (16%)
0.68
Diabetes mellitus
224
8 (4%)
1197
172 (14%)
<0.001
Body mass index, kg/m2
0
—
1080
28.6 ± 6.4
—
Use of lipid-lowering medications
224
0 (0%)
1197
125 (12%)
<0.001
Any systemic treatment
224
36 (16%)
1197
162 (14%)
0.31
Total cholesterol, mg/dL
36
220.3 ± 40.8
968
205.7 ± 35.1
0.032
LDL, mg/dL
34
138.0 ± 39.0
957
120.3 ± 34.8
0.005
HDL, mg/dL
34
46.2 ± 7.1
958
49.9 ± 8.3
0.019
Triglyceride values, mg/dL
15
196.9 ± 96.9
688
165.9 ± 110.2
0.11
Values in the table are (%) or mean ± SD. LDL: low density lipoprotein; HDL: high density lipoprotein; SD: standard deviation.
